HOUSTON, Sept. 4, 2007 (PRIME NEWSWIRE) -- Encysive Pharmaceuticals (Nasdaq:ENCY) today announced that the Company has completed patient enrollment in the Phase II trial for Sitaxsentan sodium (Thelin(tm)) in the treatment of diastolic heart failure (DHF). DHF is a type of congestive heart failure (CHF).
